175 related articles for article (PubMed ID: 35142401)
1. Systematic review of the efficacy, effectiveness and safety of MF59
O Murchu E; Comber L; Jordan K; Hawkshaw S; Marshall L; O'Neill M; Ryan M; Teljeur C; Carnahan A; Pérez JJ; Robertson AH; Johansen K; Jonge J; Krause T; Nicolay N; Nohynek H; Pavlopoulou I; Pebody R; Penttinen P; Soler-Soneira M; Wichmann O; Harrington P
Rev Med Virol; 2023 May; 33(3):e2329. PubMed ID: 35142401
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis.
Minozzi S; Lytras T; Gianola S; Gonzalez-Lorenzo M; Castellini G; Galli C; Cereda D; Bonovas S; Pariani E; Moja L
EClinicalMedicine; 2022 Apr; 46():101331. PubMed ID: 35360146
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.
Seo YB; Choi WS; Lee J; Song JY; Cheong HJ; Kim WJ
Clin Vaccine Immunol; 2014 Jul; 21(7):989-96. PubMed ID: 24828092
[TBL] [Abstract][Full Text] [Related]
4. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G
Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
Essink B; Fierro C; Rosen J; Figueroa AL; Zhang B; Verhoeven C; Edelman J; Smolenov I
Vaccine; 2020 Jan; 38(2):242-250. PubMed ID: 31635976
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of the efficacy, effectiveness and safety of cell-based seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
Jordan K; Murchu EO; Comber L; Hawkshaw S; Marshall L; O'Neill M; Teljeur C; Harrington P; Carnahan A; Pérez-Martín JJ; Robertson AH; Johansen K; Jonge J; Krause T; Nicolay N; Nohynek H; Pavlopoulou I; Pebody R; Penttinen P; Soler-Soneira M; Wichmann O; Ryan M
Rev Med Virol; 2023 May; 33(3):e2332. PubMed ID: 35137512
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.
Herbinger KH; von Sonnenburg F; Nothdurft HD; Perona P; Borkowski A; Fragapane E; Nicolay U; Clemens R
Hum Vaccin Immunother; 2014; 10(1):92-9. PubMed ID: 24047817
[TBL] [Abstract][Full Text] [Related]
9. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli G; Groth N; Del Giudice G
Hum Vaccin Immunother; 2012 Feb; 8(2):216-27. PubMed ID: 22426371
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis.
Coleman BL; Sanderson R; Haag MDM; McGovern I
Influenza Other Respir Viruses; 2021 Nov; 15(6):813-823. PubMed ID: 34081398
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
12. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
Nolan T; Bravo L; Ceballos A; Mitha E; Gray G; Quiambao B; Patel SS; Bizjajeva S; Bock H; Nazaire-Bermal N; Forleo-Neto E; Cioppa GD; Narasimhan V
Vaccine; 2014 Oct; 32(46):6146-56. PubMed ID: 25223266
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
Comber L; O Murchu E; Jordan K; Hawkshaw S; Marshall L; O'Neill M; Teljeur C; Ryan M; Carnahan A; Pérez Martín JJ; Robertson AH; Johansen K; de Jonge J; Krause T; Nicolay N; Nohynek H; Pavlopoulou I; Pebody R; Penttinen P; Soler-Soneira M; Wichmann O; Harrington P
Rev Med Virol; 2023 May; 33(3):e2330. PubMed ID: 35119149
[TBL] [Abstract][Full Text] [Related]
15. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines.
Hauser MI; Muscatello DJ; Soh ACY; Dwyer DE; Turner RM
Vaccine; 2019 Jul; 37(31):4246-4255. PubMed ID: 31253447
[TBL] [Abstract][Full Text] [Related]
16. Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults.
Domnich A; Panatto D; Pariani E; Napoli C; Chironna M; Manini I; Rizzo C; Orsi A; Icardi G;
Int J Infect Dis; 2022 Dec; 125():164-169. PubMed ID: 36332902
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.
Cheong HJ; Song JY; Heo JY; Noh JY; Choi WS; Park DW; Wie SH; Kim WJ
Clin Vaccine Immunol; 2011 Aug; 18(8):1358-64. PubMed ID: 21715575
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
O Murchu E; Comber L; Jordan K; Hawkshaw S; Marshall L; O'Neill M; Ryan M; Teljeur C; Carnahan A; Pérez JJ; Robertson AH; Johansen K; Jonge J; Krause T; Nicolay N; Nohynek H; Pavlopoulou I; Pebody R; Penttinen P; Soler-Soneira M; Wichmann O; Harrington P
Rev Med Virol; 2023 May; 33(3):e2331. PubMed ID: 35106885
[TBL] [Abstract][Full Text] [Related]
19. MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications.
Patel SS; Bizjajeva S; Heijnen E; Oberye J
Int J Infect Dis; 2019 Aug; 85S():S18-S25. PubMed ID: 31051279
[TBL] [Abstract][Full Text] [Related]
20. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
